Back

Pretreatment with dual antiplatelet therapy in acute myocardial infarction

30 August 2024 (12:40 - 12:50)
Organised by: Logo
Congress Presentation Part of: Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Zuzana Motovska

Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague (Czechia)

5 More presentations in this session

Presentation thumbnail
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention - a nationwide population-based study
Mr J. Cho (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Implementation of prasugrel and prognostic outcomes after percutaneous coronary intervention for myocardial infarction: a nationwide observational study
Doctor M. Jacobsen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Impact of different P2Y12 inhibitors in acute coronary syndrome patients with severe chronic kidney disease: insights from the CORALYS registry
Doctor F. Giacobbe (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Cangrelor versus no cangrelor during percutaneous coronary intervention in hemodynamically unstable patients: a cohort study on benefits and risks
Mr O. Emilsson (Lund, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention
Video

The Event

Event poster

ESC Congress 2024

30 August 2024 12:40 CET
You may be interested in
thumbnail
Congress Session
Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention
thumbnail
Congress Session
Adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
Should 12 months of dual antiplatelet therapy still be the default recommendation after primary PCI?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources